Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Colorectal Neoplasms 215Rectal Neoplasms 85Colonic Neoplasms 76Stomach Neoplasms 56Pancreatic Neoplasms 44Neoplasm Metastasis 40Esophageal Neoplasms 37Neoplasms 28Lung Neoplasms 27Carcinoma, Non-Small-Cell Lung 20Small Cell Lung Carcinoma 19Adenocarcinoma Of Esophagus 19Glioblastoma 18Glioma 17Neuroblastoma 16Esophageal Squamous Cell Carcinoma 16Brain Neoplasms 16Breast Neoplasms 15Sarcoma 11Gliosarcoma 10Biliary Tract Neoplasms 10Central Nervous System Neoplasms 9Astrocytoma 8Adenocarcinoma 8Oligodendroglioma 7Medulloblastoma 7Colorectal Cancer Metastatic 7Rhabdomyosarcoma 6Recurrence 6Locally Advanced Rectal Cancer 6

Interventions

lutetium Lu 177 dotatate 2copper dotatate CU-64 2Etoposide 2zimberelimab 1folfirinox 1famitinib 1cabozantinib 1abemaciclib 1Temozolomide 1Nivolumab 1Lutetium-177 1Lutetium 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Cytokines 1Cryotherapy 1Copper 1Cisplatin 1Carboplatin 1Acupuncture Therapy 1Acupressure 164Cu-DOTATATE 1177Lu-octreotide, DOTA(0)-Tyr(3)- 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastro-enteropancreatic neuroendocrine tumor × Irinotecan × Clear all
NCT03963193 2019-05-24

Etoposide/Cisplatin Compared With Irinotecan/Cisplatin for Advanced Gastrointestinal Neuroendocrine Tumor G3 Type

Henan Cancer Hospital

Phase 2 Unknown
112 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡